Drugs / BEL-X-HG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03256331 | Jun 2017 → Mar 2020 | cancer | Belx Bio-Pharmaceutical (Taiwan) Corporation | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BEL-X-HG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03256331 ↗ |
| Route | Oral | “BEL-X-HG will be administered orally at the assigned dose level” NCT03256331 ↗ |